MedPath

Fortification and supplementation effect on vitamin D levels

Phase 3
Conditions
.
Registration Number
IRCT20180708040401N2
Lead Sponsor
Shiraz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
99
Inclusion Criteria

18-30 years old
The absence of diseases which influence the metabolism of Ca, P and vitamin D such as thyroid and parathyroid disorders, chronic kidney disease, osteoporosis, or bone fractures caused by osteoporosis, during the past year
The absence of cardiovascular disease, diabetes, chronic digestive diseases, hepatitis and cancer
No medical treatment for hypertension or hyperlipidemia
Not using nutritional supplements
No pregnancy and lactation
Not participating in other studies in the last 6 months

Exclusion Criteria

The presence of diseases affecting the metabolism of phosphorus, calcium and vitamin D
The presence of cardiovascular disease, diabetes, chronic diseases of the digestive tract, hepatitis and cancer
Medical treatment for hypertension or hyperlipidemia
Using nutritional supplements
Pregnancy and lactating
Participating in other studies in the last 6 months

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
25-hydroxy vitamin D. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Total cholesterol. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Colorimeteric assay with auto-analyzer.;LDL. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Colorimeteric assay with auto-analyzer.;HDL. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Colorimeteric assay with auto-analyzer.;TG. Timepoint: Beginning of the study (before starting intervention), at the end of the study (after the end of intervention). Method of measurement: Colorimeteric assay with auto-analyzer.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath